21.71

0.18% 0.05

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is traded at $21.71, with a volume of 572.33K. It is up +0.18% in the last 24 hours and down -14.63% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Previous Close:

$21.66

Open:

$20.975

24h Volume:

572.33K

Relative Volume:

0.22

Market Cap:

$2.19B

Revenue:

$352.57M

Net Income/Loss:

$-143.01M

P/E Ratio:

-11.99

EPS:

-1.81

Net Cash Flow:

$-153.40M

1W Performance:

-2.30%

1M Performance:

-14.63%

6M Performance:

+25.87%

1Y Performance:

-17.52%

1-Day Range:

$20.76

$21.87

1-Week Range:

$20.76

$24.08

52-Week Range:

$13.53

$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1129)

Industry

Biotechnology (618)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

510

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	21.67	2.20B	352.57M	-143.01M	-153.40M	-1.81
VRTX Vertex Pharmaceuticals Inc	435.18	110.25B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	691.84	73.04B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	453.94	59.98B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	891.99	54.90B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	193.68	40.73B	447.02M	-1.18B	-906.14M	-6.1812

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

08:53 AM

Why retail investors favor Beam Therapeutics Inc. stockTrade Risk Summary & Entry Point Confirmation Signals - Fundação Cultural do Pará

08:53 AM

07:12 AM

Beam Therapeutics (BEAM): Exploring Valuation as Clinical Milestones Revitalize Investor Interest - Yahoo Finance

07:12 AM

03:32 AM

Historical volatility pattern of Beam Therapeutics Inc. visualizedJuly 2025 Spike Watch & Real-Time Chart Breakout Alerts - newser.com

03:32 AM

Nov 13, 2025

How Beam Therapeutics Inc. stock compares to market leadersJuly 2025 Volume & Trade Opportunity Analysis - newser.com

Nov 13, 2025

How to monitor Beam Therapeutics Inc. with trend dashboards2025 Buyback Activity & Weekly Stock Breakout Alerts - newser.com

Nov 13, 2025

Institutional scanner results for Beam Therapeutics Inc.Market Growth Review & Community Consensus Trade Signals - newser.com

Nov 13, 2025

Why Beam Therapeutics Inc. stock is favored by pension fundsJuly 2025 Price Swings & Expert Curated Trade Setup Alerts - newser.com

Nov 13, 2025

Nov 12, 2025

What hedge fund activity signals for Beam Therapeutics Inc. stock2025 Market WrapUp & Risk Controlled Daily Plans - newser.com

Nov 12, 2025

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference - The Globe and Mail

Nov 12, 2025

Analyzing drawdowns of Beam Therapeutics Inc. with statistical toolsPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com

Nov 12, 2025

Nov 10, 2025

Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results - MSN

Nov 10, 2025

Nov 09, 2025

15 Stocks Set to Explode in 2026 - Insider Monkey

Nov 09, 2025

Beam Therapeutics Stock (BEAM) Opinions on Clinical Trial Updates - Quiver Quantitative

Nov 09, 2025

Beam Therapeutics Bets Big On Precision Gene Editing - Finimize

Nov 09, 2025

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - FinancialContent

Nov 09, 2025

Nov 08, 2025

How buybacks impact Beam Therapeutics Inc. stock valueWeekly Loss Report & Safe Capital Growth Tips - newser.com

Nov 08, 2025

Nov 07, 2025